Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
They spread an ocassional
1/2 @ Hard Rock Tampa.
Missling is invited anytime, unless he thinks that is beneath him.
Haven't relied on a paycheck since '07.
Not quite that young. You do know that ERN HEAVEN is now an 18 yo!
Do you know how much it will cost to run a P4 for AD?...Just think of the number of patients who will take the prescription....Thinking of that....We need more pills available!!
And you know all about running a show?
LMAO!!
He likes to run his show his way and not have to be held to account.
Misleading went back to LPC even though he could have gone traditional way to raise capital
Messling needed to be gone back in 2019.
He’s just too incompetent missing every self-imposed Milestone and just announcing more toxic dilution. What an SOB.
No wonder employees are still on winter break living luxurious lifestyle knowing Shareholders will foot the bill for their NEVER missed yearly bonuses and salary increases.
LOL!!
Can't wait for criminal charges to be levied and see perp walks from the corrupt hedge funds. Will we be missing some familiar names?
Keep depositing your NWBO and AVXL shares, you will get good return in 50year...collect in grave.
That’s a remarkable causal link. I wonder why the FDA will even bother reviewing the Alz data. The fact that AVXL signed an ATM agreement proves that the data are bad. Congrats on the worst dot connecting in the history of this board.
There is no difference between the Cantor ATM and the LPC ATM in that respect. I have always favored ATMs over one-time offerings—less opportunity for tanking the pps to get a lower offering price. Missling gets to choose when, and at what price, he issues shares. An excellent move, this ATM, in my opinion. We don’t need it now but it will be there if needed.
It’s not necessarily that the AD data is bad, although it certainly could be. I think it has more to do with the fact that Missling does not want to have to answer to institutional investors. He likes to run his show his way and not have to be held to account. It should be obvious to all but the willfully blind that Missling is a one-man band who answers to no one, including his weak board of directors and his shareholders.
I’m sure a lot of people on this board disagrees with most anything that you say.
Don’t really have a winning track record
Meanwhile - And yet https://www.yahoo.com/entertainment/had-bought-anavex-life-sciences-123405650.html And since that article was written the stock has soared from $3.17 to over $11! What an amazing return for investors.
Check this LPC article. Misleading went back to LPC even though he could have gone traditional way to raise capital tells me AD data is not good and it will never come out, he might quietly announce another phase 3. Rett not sure data readout will happen this year, for NDA he need detail data and that takes years for him, PDD no one cares anymore.
LPC vulture
Then Missling needs to get his ass and the NDA to the FDA and stop dragging his feet. Not set up another ATM the same day he announces we have 4 years of cash.
We credit Dr.M. that this is not just a conventional card game of wits. AD is about people (family members) getting treatment or not for a disease that will kill them. The sooner a few liars-criminals-get executed to demonstrate seriousness ,, the better.
I've always suspected it, but now we know from where he gets his post material...
At last count, Anavex was one of the most heavily shorted biotech stocks in the market.
All that being said, this biotech stock does have a handful of uber-bullish supporters on Wall Street.
Was able to pick up a few again this morning:) ++++
He saw the writing on the wall, or was it bowl.
As in toilet bowl
I’ve been cleaning my toilet.
High stakes poker being witnessed here.
Odds aside, pun intended, human nature is explained in a high stakes poker table.
Who would of thought Dr.M was a grand master at poker too?
Oh by the way did we loose investor?
Did he finally sell all his shares?
Is it small enough to be negative?
How many shares do you owe?
Asking for a friend...
Though my position is now very small
Look, I report the news, that's what I do.
I agree. And this is where I think many shareholders will regret cheering on corporate stock buybacks when cash flow was rolling.
Assuming Missling wants to release ATM shares to LPC:
Who do you think will be calling Lincoln Park Capital for shares? Hedge Funds? Others?
If the price goes up above $13.50, I would assume that some of the short inventory will be reduced as much as they can to cover by some short sellers...so I guess I'll watch the price and volume, etc. for some sort of momentum increase before another news event!
Missling apparently wants "something positive to happen" before his 500,000 options expire on July 5th struck at $1.67....I watch price and volume action to get on the right side of this....
BTW, I believe next short interest report comes after the close on Feb. 9th
we may even break $12 today.JUST HOLD ON TIGHT LOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOONGS
Yea, the people who have bought and held for the last few years are broke now - And yet https://www.yahoo.com/entertainment/had-bought-anavex-life-sciences-123405650.html And since that article was written the stock has soared from $3.17 to over $11! What an amazing return for investors.
looking great today with all the ATM noise.HOLD ON TIGHT LOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOONGS
2 years… is the cash on hand..
As our company grows.. he grows cash on hand to be for two years..
If you want less dilution .. get a higher MC
Nobody was pleased with the decision to sell stock in 2021
Seeing good counterpoints to the negative FUD lately, good work.
File this under "U" for uncertainty that both bulls and bears will speculate on:
2). I'm slowly leaning toward a P4 (vs. outright approval) for AD and thus the case to raise cash. Most likely will be announced after RETT data in July. Remember a P4 will cost big dollars to monitor everyone prescribed!!!!
Turns out the agencies have a bit of say in that and we will have to wait until they opine.
Once it becomes clear what the path forward is on AD only then will Missling begin negotiations on a partnership.
So I think your prognostications are premature and based on nothing.
There was never any prospect of a pharma partnership this year or any other year, nor any prospect that the so-called phase 2B/3 AD trial would be pivotal.
Actually perhaps the biggest disagreement with some of the
expressed views here (not just yours).
While Revenue may be the unrealistic hope near term of a certain
contingent, it WILL require more not less expenditure.
It is likely years not weeks away and certainly not by 2/10.
We will know this time next year with three additional quarterly
financials if I am correct. Let's call it Febish '24 and cause a real stir.
Burn rate should be reduced by the conclusion of the Rett and AD trials, until additional trials are started.
Thank you powerwalker...thank you...WGT...
I like that Steve Forbes identifies himself as "Forbes Staff."
I think he and/or his foundation has bought a good number of shares in AVXL, SAVA and ANVS after his team did the research for this article.
I agree. The ATM is used on an as needed basis. If the revenues start coming in then the ATM won't be used. Sounds like a great way to line up funds.
Last time there was a big pop in the share price Missling used the ATM to raise a chunk of cash at the opportune time. To raise that same amount of money now or after that raise would take a lot more shares than it did at the time.
Seems like very good financial management to me.
So Powerwalker, then looks like that old expression ..."You are NOT CRAZY, they REALLY ARE AFTER YOU...!!!....comes to mind.
Steve Forbes Forbes Staff
“With all thy getting, get understanding."
Feb 7, 2023,06:00am EST
Why is there no cure for Alzheimer’s—or why aren’t there medications that can at least substantially slow or meaningfully ameliorate the disease? It afflicts more than 6 million Americans, with that number on its way to doubling within a generation.
Alzheimer’s is a hideous ailment for both the sufferers and their families and friends. Yet even though the disease was first diagnosed by psychiatrist Alois Alzheimer in the early 1900s, progress in fighting it has been almost nonexistent. What’s scandalous is that for decades research has been almost entirely focused on the wrong hypothesis.
Dr. Alzheimer noted in the autopsy of the patient’s brain with the disease that came to bear his name that it was densely loaded with two proteins called plaques and tangles. Unfortunately, the dominant thesis in research on the disease has been that attacking plaques, and to a lesser extent tangles, would cure the ailment and enable the brain to regain its health.
Alzheimer himself warned about focusing too much on plaques and tangles as causes. In fact, some sufferers of Alzheimer’s have proved to have had little in the way of plaques, while others who had plaques didn’t have the disease.
Nonetheless, despite constant failures—some 20 drugs have been developed that ended up as flops—and the expenditure of tens of billions of dollars, the main thrust of research remains focused on fighting plaques.
The obsession with this dead-end approach has been fanatical, almost cultlike. Researchers who want to pursue more promising avenues have faced serious obstacles. Rarely has chronic failure resisted correction on something so important.
You may have heard of a new drug called lecanemab, which is being heralded as a fantastic breakthrough. But lecanemab is based on the wrongheaded plaques hypothesis. As noted health policy journalist Joanne Silberner sadly points out, “At best, lecanemab might slightly slow a patient’s inevitable decline for a few months.”
This research scandal shows the danger of groupthink, particularly when there’s a powerful government agency such as the National Institutes of Health putting the kibosh on grants for nonconsensus projects.
A classic case of similar groupthink involved the cause of stomach ulcers. The once-prevailing view was that stress and lifestyle were the cause, and drugs and regimens were developed on that belief.
This dogma was challenged by two Australian physicians, Robin Warren and Barry Marshall. They posited that the villain was bacteria and that antibiotics were the answer for a permanent cure. When not ignored, their discoveries were derided. Only after many years and constant, sometimes unorthodox advocacy, especially by Dr. Marshall, did the medical world accept their truths. The two were eventually awarded the Nobel Prize in Medicine.
In the case of Alzheimer’s, the rigid research mentality has begun to soften, but only slightly. To attack this deadly rigidity, Congress should hold hearings on the subject, starting with the leaders at the National Institutes of Health.
Steve Forbes is Chairman and Editor-in-Chief of Forbes Media.
https://www.forbes.com/sites/steveforbes/2023/02/07/the-scandal-of-alzheimers/?sh=34284da66a41&bsft_aaid=a4679c91-eb03-4591-93c2-79b7f25f9cbd&bsft_eid=15374f1b-1165-4402-b482-cdabfc723dde&utm_source=blueshift&bsft_clkid=39bb3ca5-f842-4f84-a918-78a3d2514c58&bsft_uid=8a4ab049-cac4-4359-ae99-bc1e70d3b870&bsft_mid=6fae9050-ef21-411e-9d1c-4e5f7b0849ca&bsft_utid=8a4ab049-cac4-4359-ae99-bc1e70d3b870-DRPROOF&bsft_mime_type=html&bsft_ek=2023-02-07T21%3A30%3A36Z&bsft_lx=20&bsft_tv=4&pk=ce01a6586b8394cd219d9d4151b05359&utm_campaign=DAP_ISSUE_02.07.23&utm_medium=email&vid2=9cd562d8abdeeda86039a61cc7e5dc63e585d49a727e626584f7ccd81870dffd80f6507937c7784a56ba72af38c88171
Bullish
BULLISH
Not SO worried about catastrophic monetary collapse, just an extended
period of "real cost" borrowing.
It has been an amazing decade or so of absolutely FREE money for many.
Some of those (Corporate and Retail alike) will be ill prepared to
roll accumulated debt to current instruments.
nidan, I like that Steve Forbes identifies himself as "Forbes Staff."
I think he and/or his foundation has bought a good number of shares in AVXL, SAVA and ANVS after his team did the research for this article.
Puzzle me this....
IF the current burn rate WILL rise in part at least by added staff
let alone trial(s) expense
How long does $140M last while considering lead time to raise?
There was never any prospect of a pharma partnership this year or any other year, nor any prospect that the so-called phase 2B/3 AD trial would be pivotal. It’s amazing to watch this 3rd rate company and CEO year in and year out pulling the same well-worn nonsense, and it’s even more amazing that there are still people who continue believe it hook, line and sinker. It’s no wonder the shorts are all over this thing.
FUD = Facts, Understanding and Data, except in Candyland where a few people still believe in fairy tales.
Anavex is a good trading stock but that’s it.
All the more reason to raise money now, if one suspects an economic collapse and the cost of borrowing to increase a few years from now.
Nobody was pleased with the decision to sell stock in 2021, but that turned out to be a prudent short-term move to shore up the balance sheet. It's much harder to acquire a financially healthy company for cheap than one that has the potential to become a money pit for the acquirer.
It isn't about the money...it is about the lie..."no new taxes"...
Diversity, most importantly.
As Moon pointed out, I bonds best deal on the street....but restricted.
The only long term rate I advantage is existing mortgage(s).
Old enough to remember 11% 30year and a generation is complaining
about 6-7%.
Missling included, lets see how cost of money affects the next few years.
It's an insurance policy. Nothing more. It'll cost a small amount of capital to secure the right to raise money in the future, if it's needed.
I don't see what the big deal is. But for the sake of argument let's suppose that Dr. Missling taps into his 200mm authorized share limit and forces LPC to purchase the full $150mm worth of shares, at say $10/share. Anavex would then have $290mm in cash, no debt, and just over 100mm shares outstanding.
What's so bad about that situation? This is a non-issue. LPC funding was much scarier when the stock traded under $2.
They have 4 years cash with their currently plans
Followers
|
1071
|
Posters
|
|
Posts (Today)
|
101
|
Posts (Total)
|
462350
|
Created
|
12/18/07
|
Type
|
Free
|
Moderators RedShoulder Steady_T Bourbon_on_my_cornflakes kund mike_dotcom nidan7500 |
Anavex®Life Sciences Corp. (the “Company”) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including drug candidates to treat Alzheimer’s disease, other central nervous system (“CNS”) diseases, pain and various types of cancer. The Company’s lead compound ANAVEX®2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome.
Anavex®Life Sciences’ lead drug candidate, ANAVEX®2-73, recently completed successfully a Phase 2a clinical trial for Alzheimer’s disease. ANAVEX®2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. It has also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy and others. The Michael J. Fox Foundation for Parkinson’s Research has awarded Anavex® a research grant to develop ANAVEX®2-73 for the treatment of Parkinson’s disease to fully fund a preclinical study, which could justify moving ANAVEX®2-73 into a Parkinson’s disease clinical trial. ANAVEX®3-71, also targeting sigma-1 and M1 muscarinic receptors, is a promising preclinical drug candidate demonstrating disease modifications against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also with beneficial effects on neuroinflammation and mitochondrial dysfunctions.
The Company is in preparation for ANAVEX®2-73 for a Phase 2/3, placebo-controlled trial in Alzheimer’s disease as well as a Phase 2, placebo-controlled trial in Rett syndrome, for which the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for ANAVEX®2-73 and a Phase 2, placebo-controlled trial in Parkinson’s disease.
Headquartered in New York, Anavex® Life Sciences is an American publicly traded corporation on Nasdaq quoted as AVXL
.Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |